Arvinas (NASDAQ:ARVN) CAO Sells $12,080.24 in Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David Loomis sold 1,016 shares of Arvinas stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $11.89, for a total transaction of $12,080.24. Following the completion of the transaction, the chief accounting officer directly owned 30,800 shares of the company’s stock, valued at $366,212. This trade represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Arvinas Price Performance

Shares of NASDAQ:ARVN traded up $0.38 during trading on Wednesday, reaching $11.82. 559,743 shares of the company’s stock traded hands, compared to its average volume of 759,739. The stock has a market capitalization of $759.13 million, a P/E ratio of -14.59 and a beta of 1.88. Arvinas, Inc. has a 12 month low of $5.90 and a 12 month high of $19.40. The company has a 50 day moving average of $12.40 and a 200-day moving average of $10.32.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ARVN. AQR Capital Management LLC bought a new position in shares of Arvinas during the 1st quarter valued at about $727,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Arvinas during the first quarter valued at approximately $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Arvinas by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after purchasing an additional 2,122 shares in the last quarter. Millennium Management LLC boosted its position in shares of Arvinas by 208.4% in the first quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after buying an additional 885,483 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Arvinas by 108.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock worth $6,339,000 after buying an additional 469,394 shares during the period. Institutional investors own 95.19% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on ARVN shares. Wedbush reissued a “neutral” rating and issued a $9.00 price target on shares of Arvinas in a report on Thursday, November 6th. Citigroup raised Arvinas from a “neutral” rating to a “buy” rating and increased their target price for the stock from $10.00 to $15.00 in a research report on Tuesday, January 6th. Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a research note on Saturday. Stephens upped their price target on shares of Arvinas from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, November 10th. Finally, BTIG Research lifted their price objective on shares of Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Ten equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Arvinas currently has a consensus rating of “Hold” and a consensus target price of $13.12.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.